Protective matrix for intracorporeal biosensors that improves gastrointestinal leak detection, detects air leaks after lung surgery, and measures cardiac output after heart surgery

Tech ID:
2011.079.HSCS
Description:

This device is a multifaceted platform technology that can perform a variety of functions including but not limited to measuring cardiac output after heart surgery, detecting air leaks after lung surgery. The device can directly measure physiological changes at a desired organ, tissue, and/or site.

 

This site may be any portion of the body including heart, lungs, gastrointestinal tract, or proximate other organs. This device contains sensors that can detect movement of organs or leaks proximate to the site where the sensors are disposed. This device may be used to measure cardiac contractility. Currently there is no other direct method available to measure the cardiac contractility and measuring cardiac contractility is important because a decrease in this value ultimately represents pump failure of the heart.

 

This device consists of electrolytic biosensors embedded in a porous protective matrix. The porous matrix may be positioned in a body at a site to be monitored. The porous matrix may be formed from a flexible material that may allow the shape of the porous matrix to be selected to facilitate impedance monitoring at a desired site. The sensors can be configured to analyze, calculate and/or display impedance at the desired site or organ. The sensors can externally transmit impedance data and related messages using existing network infrastructure and/or to mobile user device.

 

Background

 

Decrease in cardiac contractility may occur due to myocardial ischemia, rejection or reperfusion injury in cardiac transplantation, fluid overload in the case of congestive heart failure, or other injury or pathology of the myocardium. Direct measurement of cardiac contractility is important as it could represent a means of earlier identification of cardiac failure allowing for earlier intervention. This device can also measure lung compliance with high sensitivity without damaging the lung tissue. Lung compliance, like cardiac contractility, may change in certain pathological conditions such as pulmonary edema, pulmonary injury, pulmonary infection, respiratory distress syndrome, or graft rejection or ischemia/reperfusion injury after lung transplant. The device could be used to measure pathologic changes in other tissues as a result of edema, ischemia, infection, rejection, or other pathology.

 

Commercial Applications & Advantages:

Key Applications

·         Physiological change monitoring biosensors embedded in a porous matrix. The sensors may be placed in the body to directly measure physiological changes at a desired organ, tissue and/or site. This device can measure changes in cardiac contractility, lung compliance, leaking anastomosis. Other potential target tissues could be, limb tissues after injury or vascular surgery, liver after resection, repair or transplantation, kidney after resection, repair, brain trauma or surgery, major blood vessels including aorta, etc. after trauma or surgery.

 

 

Key Advantages:

·         Permits accurate and direct measurement of the physiological state of an organ; allows the medical team to diagnose problems early, before the development severe complications.

·         Based on inexpensive and well characterized components; the electrolytic biosensor can transmit patient data and related messages using existing network infrastructure and/or to mobile user device.

·         Simple and robust components offers built-in reliability and low per-unit costs

·         Adoption of the device does not require any change in the practice of clinicians; drains are commonly used in these procedures. Patients will benefit from a lower overall rate of complications and clinicians will benefit from earlier and more precise diagnosis of problems ? with a very short learning curve.

·         The small size and portability of the system ensures that measurements can be taken at the patient?s bedside; no need to transport an already suffering patient to the radiography lab for contrast medium imaging as is the current practice

·         Sensors embedded in a protective matrix; very small chance that components will be retained in the patient upon device removal - safe

 

Inventor:  Daniel T. DeArmond, M.D.

 

Patent Status: One issued patent (Appl. no: 11/077,178) and two others are pending.

 

Contact Information:             John A. Fritz

                                                 Sr. Business Development Manager

                                                 (210) 562-4033    fritzja@uthscsa.edu

Patent Information:
Category(s):
Medical Devices
For information contact:
John Fritz
Sr. Business Development Manager
Office of Technology Commercialization
FRITZJA@UTHSCSA.EDU
Inventors:
Daniel DeArmond
Keywords: